We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




FIT Hemoglobin Predicts Risk of Advanced Neoplasia

By LabMedica International staff writers
Posted on 09 Nov 2017
Colorectal cancer (CRC) screening using quantitative fecal immunochemical tests (FITs) is rapidly gaining ground worldwide and FITs are invariably used in a dichotomous manner using pre-specified cut-off values.

Hemoglobin (Hb) concentration in fecal immunochemical test (FIT) results during the first round of colorectal cancer (CRC) screening is an independent predictor of risk of advanced neoplasia (AN) and might be used in designing personalized strategies for CRC screening while reducing unnecessary repeat tests.

Gastroenterologists at the Erasmus MC University Medical Centre (Rotterdam, The Netherlands) analyzed data collected from a population-based study of 9,561 average-risk subjects (50-74 years old) in the Netherlands who were offered four rounds of FIT screening for CRC from November 2006 through December 2014. More...
They analyzed data from 7,663 participants screened at least once and found to have a negative FIT result at baseline (below the cut-off value of 10 μg Hb/ gram of feces [G]). Participants were followed for a median of 4.7 years (interquartile range, 2.0-6.1 years).

The investigators found that participants with two consecutive FIT Hb concentrations equal to or greater than 8 µg/G had a 14-fold increased risk of AN compared to those with baseline concentrations of 0 µg/G. Multi-variate hazard ratios increased from 1.2 for participants with FIT Hb concentrations 0–2 µg/G to 8.2 for those with concentrations 8–10 µg/G. This rising cumulative incidence of AN based on elevated FIT Hb levels was more prominent for Hb concentrations between 4 µg/G and 10 µg/G.

The authors concluded that in a population-based study of average-risk individuals with a FIT result below the cut-off value,they associated baseline concentrations of 8-10 μg fecal Hb/G with an increased risk of AN compared with baseline concentrations of 0 μg fecal Hb/G. Baseline and consecutive fecal Hb concentrations are independent predictors for incident AN. This information might be used in designing personalized strategies for population-based CRC screening and reduce unnecessary repeat tests. The study was originally published on July 28, 2017, in the journal Gastroenterology.

Related Links:
Erasmus MC University Medical Centre


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
POC Immunoassay Analyzer
Procise DX
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Avantect Pancreatic Cancer Test combines epigenomic, genomic, and glycan biomarkers with machine learning to detect pancreatic cancer-associated signals in blood (Photo courtesy of ClearNote Health)

Multiomic Blood Test Supports Noninvasive Monitoring and Subtyping in Pancreatic Cancer

Pancreatic ductal adenocarcinoma remains difficult to detect early and monitor during treatment, particularly in patients with homologous recombination defects. Clinicians also have limited noninvasive... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: The model combines digitized tumor histopathology, clinical variables, and a 42-gene molecular panel using AI to generate a unified recurrence risk prediction (Image Credit: Shutterstock)

Multimodal AI Improves Breast Cancer Recurrence Risk Prediction Beyond Standard Genomic Testing

Predicting which patients with early-stage breast cancer will develop distant recurrence remains difficult, complicating decisions about long-term therapy and surveillance. Widely used genomic assays are... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.